Biogen to get speedy FDA review for Alzheimer’s drug despite not using voucher to request it August 7, 2020 Auto Bot aducanumab, alzheimer's disease, Biogen, BioPharma, biopharma nl, Cambridge, Eisai, FDA, Massachusetts, Tokyo 0 Biogen and Eisai said the FDA had accepted and given priority review to their application for aducanumab. The drug will undergo an advisory committee meeting at an undisclosed date. Biogen’s stock rose 10%, but analysts had mixed opinions.